CA2208924A1 - Sparing paclitaxel by the use of hyaluronan - Google Patents
Sparing paclitaxel by the use of hyaluronanInfo
- Publication number
- CA2208924A1 CA2208924A1 CA002208924A CA2208924A CA2208924A1 CA 2208924 A1 CA2208924 A1 CA 2208924A1 CA 002208924 A CA002208924 A CA 002208924A CA 2208924 A CA2208924 A CA 2208924A CA 2208924 A1 CA2208924 A1 CA 2208924A1
- Authority
- CA
- Canada
- Prior art keywords
- amount
- hyaluronan
- paclitaxel
- dosage amount
- less
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Abstract
This invention relates to the use of forms of hyaluronan for use to deliver effective dosage amounts of the agent paclitaxel sold under the trade mark "Taxol" to a patient which medicine is present in a dosage amount much less than the usual amount presently being used when treating a patient with cancer.
Description
TITLE OF INVENTION
Sparing Paclitaxel by the Use of Hyaluronan.
FIELD OF INVENTION
This invention relates to the use of forms of hyaluronan for use to deliver to a patient the highly lipophilic therapeutic compound paclitaxel for example sold under the trade mark Taxol and in one aspect, to deliver effective dosage amounts of paclitaxel to the patient in need thereof which amount of paclitaxel is present in an effective dosage amount which is less than the usual dosage amount used today when treating a patient having cancer. In one aspect, this 10 invention relates to the use of forms of hyaluronan to deliver amounts of thehighly lipophilic therapeutic compound paclitaxel in such amount which would today not be normally expected to provide effective treatment to a patient and which amount becomes effective for treating the patient when combined with a form of hyaluronan.
PCT Application No. WO 91 /04058 discloses the use of forms of hyaluronan for delivery of medicines and therapeutic agents for the treatment ofdiseases and conditions of patients. The treatments were for underperfused tissue and pathological tissue (see p. 24 of the PCT Application).
Among the medicines and therapeutic agents suitable for delivery by hyaluronan are lipophilic therapeutic compounds such as chemotherapeutic agents to treat the underperfused and pathological tissue including tumours.
While the usual dosage amounts known at the time of application WO 91/04058 of the agent are successfully administered by the use of hyaluronan, larger dosage 25 amounts (excess amounts) of medicines (such as NSAIDS) may also be successfully used to treat patients without the usual deleterious side effects expected. The amount of hyaluronan substantially reduces the significant deleterious side effects of for example the NSAIDS when administered together even when substantially larger dosage amounts of NSAIDS are used.
SUMMARY OF INVENTION
Applicants have now discovered that substantially lesser amounts than the usual dosage amounts of the highly lipophilic therapeutic compound paclitaxel may be successfully administered to treat patients and such lesser amounts will be effective dosage amounts in the treatment if administered with a form of hyaluronan to treat underperfused tissue and/or pathological tissue (which express excess hyaluronan receptors [more than normal tissue]) such as tumours. This unexpected finding provides the benefit to the patient of successful treatment of pathological tissue expressing excess hyaluronan 10 receptors, while receiving much less than the usual accepted dosage amount ofthe highly lipophilic agent paclitaxel. As paclitaxel is toxic, the patient is not administered as much as previously. The toxic side-effects of paclitaxel on the patient and particularly his/her liver is very much reduced. Additionally as paclitaxel is expensive (in the order of about $14,000/kg. of TaxolTM) and the 15 usual dosage of 175mg/m2 administered intravenously over 3 hours every three weeks is reduced substantially, the costs of treatment are substantially reduced.
Thus, paclitaxel for example paclitaxel diphenhydromine is "spared" (the amount being used in one dosage is substantially reduced from that normally used by itself).
It is therefore an object of this invention to provide improved formulations comprising "spared" amounts of the highly lipophilic antineoplastic agent paclitaxel for the treatment of cancer.
It is a further object of the invention to provide methods of treatment of patients using the spared amounts of the agent paclitaxel in dosage amounts of 25 formulations comprising forms of hyaluronan and which spared amounts of the agent are effective amounts for successful treatment of patients having for example cancer when administered with forms of hyaluronan and which amount of the agent paclitaxel would not otherwise be an effective amount if administered without hyaluronan. Such spared amounts of the medicine paclitaxel may be as much as about 4 - 6 times less than the usual amount of paclitaxel administered alone and still be effective when combined with hyaluronan. For example, where TaxolTM (paclitaxel) is involved, the amount of TaxolTM (paclitaxel) "spared" may be at least 3 times less (and as much as 4 - 6times less) than the usual dosage amount of the agent when administered without hyaluronan.
The accepted amount of paclitaxel usually given to a patient is in the order of 175mg/m2. In accordance with this invention, an effective amount of 10 paclitaxel sold under the trade mark TaxolTM may be in the order of 55mg/m2 or less (such as 28mg/m2) when paclitaxel is administered with the form of hyaluronan and such amount is now found to be effective in the treatment of patients suffering from cancer.
The form of hyaluronan may comprise amounts between 10mg and 15 1000mg or more in each dosage amount. As hyaluronan is not toxic, even greater amounts of hyaluronan may be used in each dosage for example up to 3000mg per dosage.
The dosages are administered to a patient as required - for example, dosages per week for the duration of treatment. The dosages may be 20 administered by injection, intravenously or directly into the tumour.
The form of hyaluronan may be selected from hyaluronan and pharmaceutically acceptable non-toxic salts thereof such as sodium hyaluronate.
Many forms of hyaluronan may be suitable for use herein although those preferred are those discussed hereafter. Molecular weights of forms of 25 hyaluronan less than about 750,000 daltons and preferably greater than 150,000 daltons (protein standard) in sterile water prepared having a viscosity for intravenous administration are suitable.
One specific form of pharmaceutical grade is a 1% sterile sodium hyaluronate solution (50 ml vials) provided by Hyal Pharmaceutical Corporation which has the following characteristics:
Tests Specifications 1. Container Description 150 mL Flint glass vial with a red or gray rubber stopper and an aluminum seal, 20 mm in size.
Sparing Paclitaxel by the Use of Hyaluronan.
FIELD OF INVENTION
This invention relates to the use of forms of hyaluronan for use to deliver to a patient the highly lipophilic therapeutic compound paclitaxel for example sold under the trade mark Taxol and in one aspect, to deliver effective dosage amounts of paclitaxel to the patient in need thereof which amount of paclitaxel is present in an effective dosage amount which is less than the usual dosage amount used today when treating a patient having cancer. In one aspect, this 10 invention relates to the use of forms of hyaluronan to deliver amounts of thehighly lipophilic therapeutic compound paclitaxel in such amount which would today not be normally expected to provide effective treatment to a patient and which amount becomes effective for treating the patient when combined with a form of hyaluronan.
PCT Application No. WO 91 /04058 discloses the use of forms of hyaluronan for delivery of medicines and therapeutic agents for the treatment ofdiseases and conditions of patients. The treatments were for underperfused tissue and pathological tissue (see p. 24 of the PCT Application).
Among the medicines and therapeutic agents suitable for delivery by hyaluronan are lipophilic therapeutic compounds such as chemotherapeutic agents to treat the underperfused and pathological tissue including tumours.
While the usual dosage amounts known at the time of application WO 91/04058 of the agent are successfully administered by the use of hyaluronan, larger dosage 25 amounts (excess amounts) of medicines (such as NSAIDS) may also be successfully used to treat patients without the usual deleterious side effects expected. The amount of hyaluronan substantially reduces the significant deleterious side effects of for example the NSAIDS when administered together even when substantially larger dosage amounts of NSAIDS are used.
SUMMARY OF INVENTION
Applicants have now discovered that substantially lesser amounts than the usual dosage amounts of the highly lipophilic therapeutic compound paclitaxel may be successfully administered to treat patients and such lesser amounts will be effective dosage amounts in the treatment if administered with a form of hyaluronan to treat underperfused tissue and/or pathological tissue (which express excess hyaluronan receptors [more than normal tissue]) such as tumours. This unexpected finding provides the benefit to the patient of successful treatment of pathological tissue expressing excess hyaluronan 10 receptors, while receiving much less than the usual accepted dosage amount ofthe highly lipophilic agent paclitaxel. As paclitaxel is toxic, the patient is not administered as much as previously. The toxic side-effects of paclitaxel on the patient and particularly his/her liver is very much reduced. Additionally as paclitaxel is expensive (in the order of about $14,000/kg. of TaxolTM) and the 15 usual dosage of 175mg/m2 administered intravenously over 3 hours every three weeks is reduced substantially, the costs of treatment are substantially reduced.
Thus, paclitaxel for example paclitaxel diphenhydromine is "spared" (the amount being used in one dosage is substantially reduced from that normally used by itself).
It is therefore an object of this invention to provide improved formulations comprising "spared" amounts of the highly lipophilic antineoplastic agent paclitaxel for the treatment of cancer.
It is a further object of the invention to provide methods of treatment of patients using the spared amounts of the agent paclitaxel in dosage amounts of 25 formulations comprising forms of hyaluronan and which spared amounts of the agent are effective amounts for successful treatment of patients having for example cancer when administered with forms of hyaluronan and which amount of the agent paclitaxel would not otherwise be an effective amount if administered without hyaluronan. Such spared amounts of the medicine paclitaxel may be as much as about 4 - 6 times less than the usual amount of paclitaxel administered alone and still be effective when combined with hyaluronan. For example, where TaxolTM (paclitaxel) is involved, the amount of TaxolTM (paclitaxel) "spared" may be at least 3 times less (and as much as 4 - 6times less) than the usual dosage amount of the agent when administered without hyaluronan.
The accepted amount of paclitaxel usually given to a patient is in the order of 175mg/m2. In accordance with this invention, an effective amount of 10 paclitaxel sold under the trade mark TaxolTM may be in the order of 55mg/m2 or less (such as 28mg/m2) when paclitaxel is administered with the form of hyaluronan and such amount is now found to be effective in the treatment of patients suffering from cancer.
The form of hyaluronan may comprise amounts between 10mg and 15 1000mg or more in each dosage amount. As hyaluronan is not toxic, even greater amounts of hyaluronan may be used in each dosage for example up to 3000mg per dosage.
The dosages are administered to a patient as required - for example, dosages per week for the duration of treatment. The dosages may be 20 administered by injection, intravenously or directly into the tumour.
The form of hyaluronan may be selected from hyaluronan and pharmaceutically acceptable non-toxic salts thereof such as sodium hyaluronate.
Many forms of hyaluronan may be suitable for use herein although those preferred are those discussed hereafter. Molecular weights of forms of 25 hyaluronan less than about 750,000 daltons and preferably greater than 150,000 daltons (protein standard) in sterile water prepared having a viscosity for intravenous administration are suitable.
One specific form of pharmaceutical grade is a 1% sterile sodium hyaluronate solution (50 ml vials) provided by Hyal Pharmaceutical Corporation which has the following characteristics:
Tests Specifications 1. Container Description 150 mL Flint glass vial with a red or gray rubber stopper and an aluminum seal, 20 mm in size.
2. Product Description A clear, colourless, odourless, transparent, slightly viscous liquid.
3. Fill Volume 50.0 to 52.0 mL
4. pH 5.0 to 7.0 at 25 degrees C.
5. Specific Gravity 0.990 to 1.010 at 25 degrees C.
6. IntrinsicViscosity 4.5 to 11.0 dL/g 7. Molecular Weight 178,000 to 562,000 daltons 8. Sodium Hyaluronate Assay 9.0 to 11.0 mg/mL. Positive and Identification 9. Particulate Matter No visible Particulate Matter 10. Sterility MeetsRequirements forSterility, 11. Bacterial Endotoxins (LAL) Meets Requirements for Bacterial Endotoxins, USP 23.
This pharmaceutical grade 1% sterile solution of hyaluronan may be made 25 from granules/powder having the following characteristics:
Tests Specifications 1. Description White or cream-coloured granules or powder, odourless 2. Identification (IR Spectrum) Must conform with the Reference Standard Spectrum.
3. pH (1% Solution) Between 5.0 and 7.0 at 25 degrees C.
4. Loss on Drying NMT 10.0% at 102 degrees C. for 6 hours.
5. Residue on Ignition Between 15.0 and 19.0%
6. ProteinContent NMT 0.10%
7. Heavy Metals NMT 20 ppm (as per USP 23 p. 1727).
8. Arsenic NMT 2 ppm (as per USP 23, p. 1724).
9. Residual Solvents a) Acetone: NMT 0.1%
b) Ethanol: NMT 2.0%
c) Formaldehyde: NMT 100 ppm 10. Sodium Hyaluronate Assay 97.0 to 102.0% (dried basis) 11. Intrinsic Viscosity Between 10.0 to 14.5 deciliters per gram.
This pharmaceutical grade 1% sterile solution of hyaluronan may be made 25 from granules/powder having the following characteristics:
Tests Specifications 1. Description White or cream-coloured granules or powder, odourless 2. Identification (IR Spectrum) Must conform with the Reference Standard Spectrum.
3. pH (1% Solution) Between 5.0 and 7.0 at 25 degrees C.
4. Loss on Drying NMT 10.0% at 102 degrees C. for 6 hours.
5. Residue on Ignition Between 15.0 and 19.0%
6. ProteinContent NMT 0.10%
7. Heavy Metals NMT 20 ppm (as per USP 23 p. 1727).
8. Arsenic NMT 2 ppm (as per USP 23, p. 1724).
9. Residual Solvents a) Acetone: NMT 0.1%
b) Ethanol: NMT 2.0%
c) Formaldehyde: NMT 100 ppm 10. Sodium Hyaluronate Assay 97.0 to 102.0% (dried basis) 11. Intrinsic Viscosity Between 10.0 to 14.5 deciliters per gram.
12. Molecular Weight Between 500,000 to 800,000 daltons (,~AI~lllA~d using the Laurent Formula) (based on intrincis viscosity).
13. Total Aerobic Microbial Count NMT 50 microorganism/gram (as per USP 23, p. 1684).
14. Test for Escherichia coli Escherichia coli is absent (as per USP
23, p. 1685).
23, p. 1685).
15. Yeasts & Molds NMT 50 microorganisms/gram (as per USP 23, p. 1686).
16. Endotoxins (LAL) NMT 0.07 EU/mg (as per USP 23, p.
1696).
A topical grade of hyaluronan may, in certain circumstances be suitable and may be made from the following granules/powder which have the following characteristics:
Tests Specifications 1. Description White or cream-coloured granules or powder, odourless 2. Identification (IR Spectrum) Must conform to the Reference Standard Spectrum.
3. pH (1% Solution) Between 6.0 and 8.0 at 25 degrees C.
4. Loss on Drying NMT 10.0% at 102 degrees C. for 6 hours.
5. Residue on Ignition Between 15.0 and 19.0%
6. ProteinContent NMT 0.40%
7. Heavy Metals NMT 20 ppm (as per USP 23 p. 1727).
8. Arsenic NMT 2 ppm (as per USP 23, p. 1724).
9. Residual Solvents a) Acetone: NMT 0.1%
b) Ethanol: NMT 2.0%
c) Formaldehyde: NMT 100 ppm 10. Sodium Hyaluronate Assay 97.0 to 102.0% (dried basis) 11. Intrinsic Viscosity Between 11.5 to 14.5 deciliters per gram.12. Molecular Weight Between 600,000 to 800,000 daltons (calculated using the Laurent Formula) (based on intrinsic viscosity).
13. Total Aerobic Microbial Count NMT 100 microorganism/gram (as per USP 23, p. 1684).
14. Test for Staphylococcus aureus Staphylococcus aureus is absent (as per USP 23, p. 1684).
15. Test for Pseudomonas aeruginosa Pseudomonas aeruginosa is absent (as per USP 23, p. 1684).
16. Yeasts & Molds NMT 200 CFU/gram (as per USP 23, p.
1686) .
This topical grade may then be sterilized.
Other forms may be suitable such as one form of hyaluronic acid and/or salts thereof (for example, sodium salt) may be an amount also supplied by Hyal Pharmaceutical Corporation. One such amount is a 15 ml vial of Sodium hyaluronate 20mg/ml (300mg/vial - Lot 2F3). The sodium hyaluronate fraction is a 2% solution with a mean average molecular weight of about 225,000. The amount also contains water q.s. which is triple distilled and sterile in accordance with the U.S.P. for injection formulations. The vials of hyaluronic acid and/or salts thereof may be carried in a Type 1 borosilicate glass vial closed by a butyl stopper which does not react with contents of the vial.
The amount of hyaluronic acid and/or salts thereof (for example sodium salt) may comprise hyaluronic acid and/or salts thereof having the following characteristics:
a purified, substantially pyrogen-free fraction of hyaluronic acid obtained from a natural source having at least one characteristic selected from the group consisting of the following:
i) a molecular weight within the range of 150,000 - 225,000;
ii) less than about 1.25% sulphated mucopolysaccharides on a total weight basis;
iii) less than about 0.6% protein on a total weight basis;
iv) less than about 150 ppm iron on a total weight basis;
v) less than about 15 ppm lead on a total weight basis;
vi) less than 0.0025% glucosamine;
vii) less than 0.025% glucuronic acid;
viii) less than 0.025% N-acetylglucosamine;
ix) less than 0.0025% amino acids;
x) a UV extinction coefficient at 257 nm of less than about 0.275;
xi) a UV extinction coefficient at 280 nm of less than about 0.25;
and, xii) a pH within the range of 7.3 - 7.9. Preferably, the hyaluronic acid is mixed with water and the fraction of hyaluronic acid fraction has a mean average molecular weight within the range of 150,000 - 225,000.
Preferably this amount of hyaluronic acid comprises at least one characteristic selected from the group consisting of the following characteristics:
i) less than about 1% sulphated mucopolysaccharides on a total weight basis;
ii) less than about 0.4% protein on a total weight basis;
iii) less than about 100 ppm iron on a total weight basis;
iv) less than about 10 ppm lead on a total weight basis;
v) less than 0.00166% glucosamine;
vi) less than 0.0166% glucuronic acid;
vii) less than 0.016% N-acetylglucosamine;
viii) less than 0.00166% amino acids;
ix) a UV extinction coefficient at 257 nm of less than about 0.23;
x) a UV extinction coefficient at 280 nm of less than 0.19; and xi) a pH within the range of 7.5 - 7.7 Other forms of hyaluronic acid and/or its salts may be chosen from other suppliers, for example those described in prior art documents disclosing forms of hyaluronic acid having lower molecular weights between about 150,000 daltons and 750,000 daltons (protein standard) being prepared as for example, 1-2%
solutions in sterile water for intravenous administration. In addition, sodium hyaluronate produced and supplied by LifeCoreTM Biomedical, Inc. having the following specifications may be suitable (if sterile):
Characteristics Specification Appearance White to cream colored particles Odor No perceptible odor Viscosity Average < 750,000 Daltons Molecular Weight UV/Vis Scan, 190-820nm Matches reference scan OD, 260nm < 0.25 OD units Hyaluronidase Sensitivity Positive Response IR Scan Matches reference pH, 10mg/g solution 6.2 - 7.8 Water 8% maximum Protein < 0.3 mcg/mg NaHy Acetate < 10.0 mcg/mg NaHy Heavy Metals, maximum ppm As Cd Cr Co Cu Fe Pb Hg N i 2.0 5.0 5.0 10.0 10.0 25.0 10.0 10.0 5.0 Microbial Bioburden None observed Endotoxin < 0.07EU/mg NaHy Biological Safety Testing Passes RabbitOcular Toxicity Test The following references teach hyaluronic acid, sources thereof and processes of the manufacture and recovery thereof.
Canadian Letters Patent 1,205,031 (which refers to United States Patent 4,141,973 as prior art) refers to hyaluronic acid fractions having average molecular weights of from 50,000 to 100,000; 250,000 to 350,000; and 500,000 to 730,000 and discusses processes of their manufacture Where high molecular weight hyaluronic acid (or salts or other forms thereof) is used, it must, prior to use be diluted to permit administration and ensure no intramuscular coagulation. Recently, it has been found that large molecular weight hyaluronic acid having a molecular weight exceeding about 1,000,000 daltons self-aggregates and thus, does not interact very well with HA
receptors. Thus, the larger molecular weight hyaluronic acid (such as HealonTM) should be avoided.
Thus, according to an aspect of the invention, the invention provides a composition comprising a therapeutically effective amount of paclitaxel with a 10 therapeutically effective amount of hyaluronic acid and/or a pharmaceuticallyacceptable salt thereof, together with a pharmaceutically-acceptable diluent wherein the therapeutically effective amount of paclitaxel is at a significantlyreduced level than would be normally used (for example greater than three times less). Thus the amount of paclitaxel reduced from that normally used, is 15 "spared" .
The invention also provides a method of treatment of a pathological condition in a subject in need of such treatment, comprising the step of administering an effective dose of a composition according to the invention to said subject over such period as may be required. For example, the treatment 20 may continue for months. However in each instance the effective amount of the agent is "spared".
The invention also provides the use of a composition comprising a form of hyaluronan and an effective dosage amount of paclitaxel for treating a pathological condition (cancer) and wherein the therapeutically effective amount25 of paclitaxel is at a significantly reduced level than would be normally used (for example greater than three times less).
It will be clearly understood that the dose and route of administration will depend upon the condition to be treated, and the attending physician will readily be able to determine suitable doses and routes.
The subject to be treated may be a human (or may be an animal).
The invention further provides a method of preparing a composition of the invention, comprising the step of combining such highly lipophilic therapeutic compound paclitaxel with hyaluronan and/or a pharmaceutically-acceptable salt thereof, and a diluent (such as sterile water) and put into a suitable pharmaceutically acceptable tolerable form (which is of course, non-toxic). The 10 agent once again will be "spared". The inventors believe that the unique attraction between hydrophobic patches of the hyaluronan and paclitaxel enable the paclitaxel to be "spared".
While hyaluronan (HA) is generally hydrophilic, it has these hydrophobic patches which Applicants believe permit the binding/association of the 15 hyaluronan with the paclitaxel. These hydrophobic patches are dispersed on the molecule. Because of the dispersion and lack of knowledge of the exact positions, it is not known if any particular compound combined with the hyaluronan would be capable of being spared to provide effective dosages to the patient.
The invention will now be illustrated with reference to the following tests 20 which illustrate the invention.
The tumour model used in the tests was that described in detail on pages 59 - 60 of Fourth International Workshop - on Hyaluronan in Drug Delivery as follows:
Colon-26 cells Colon-26 cells, a gift from the Imperial Cancer Research Fund (London), were maintained in antibiotic supplemented DMEM
containing 10% fetal calf serum at 37~C in 95% oxygen/5% carbon dioxide.
Tumour Induction Anaesthetized BALB/c mice were subcutaneously implanted with sponges (8 x 4 mm) and seeded with 106 Colon-26 cells three days later by injection.
5 The tumours were allowed to establish for 4 days before dosing was initiated.
Dosing was intravenous (0.25ml/day) for 6 days of amounts as shown in the table below and the tumours were excised 24 hours after the last dose. The data so farrelates to wet and dry weights of the tumour mass, and is shown in the following table:
Group n Wet Weight/mg Dry Weight/mg Control PBS 7 470 15 84.5+4.2 Cremophor 9 514+ 39 94.4+ 7.8 Taxol 2.5mg/kg 6 482 37 81.7 9.2 Taxol 10mg/kg 8 464+ 30 73.9 + 6.4 HA7.5mg/kg 7 485 28 72.1 + 5.3~
Taxol 2.5mg/kg + 8 391 + 38~ 60.4 + 8.0~*
HA 7.5mg/kg ~ p<0.05 ~ ~ p<0.01 comparison with Cremophor control.
HA = hyaluronan (sodium hyaluronate (EM) having a molecular weight between 50,000 and 750,000 daltons (protein standard) Taxol was solubilised in a mixture of 1:1 ethanol and cremophor EL.
15 Further dilution was in sterile PBS. The final cremophor concentration in allTaxol groups was 1.6%. A similar solution served as vehicle control (the cremophor group in the table above).The HA alone should be compared with the PBS control group. Numbers refer to dose in mg/kg.
The dry weights are of particular interest. We have a dose response reduction in dry weight with Taxol, and the combination of low dose Taxol with HA gives the greatest suppression of all.
To note: the reduction in tumour weight caused by HA alone; this is 5 significant only against the Cremophor and not the PBS control. Nonetheless, the data speaks for itself and demonstrates that HA had no detrimental effect ontumour growth. In fact it appears to suppress tumour growth possibly to the same extent as the high dose Taxol. (See PCT application WO 95/30423). The form of HA and TaxolTM may be administered in any suitable manner such as by 10 direct injection, intravenous administration etc.
As many changes can be made to the embodiments without departing from the scope of the invention, it is intended that all material contained herein be interpreted as illustrative of the invention and not in a limiting sense.
1696).
A topical grade of hyaluronan may, in certain circumstances be suitable and may be made from the following granules/powder which have the following characteristics:
Tests Specifications 1. Description White or cream-coloured granules or powder, odourless 2. Identification (IR Spectrum) Must conform to the Reference Standard Spectrum.
3. pH (1% Solution) Between 6.0 and 8.0 at 25 degrees C.
4. Loss on Drying NMT 10.0% at 102 degrees C. for 6 hours.
5. Residue on Ignition Between 15.0 and 19.0%
6. ProteinContent NMT 0.40%
7. Heavy Metals NMT 20 ppm (as per USP 23 p. 1727).
8. Arsenic NMT 2 ppm (as per USP 23, p. 1724).
9. Residual Solvents a) Acetone: NMT 0.1%
b) Ethanol: NMT 2.0%
c) Formaldehyde: NMT 100 ppm 10. Sodium Hyaluronate Assay 97.0 to 102.0% (dried basis) 11. Intrinsic Viscosity Between 11.5 to 14.5 deciliters per gram.12. Molecular Weight Between 600,000 to 800,000 daltons (calculated using the Laurent Formula) (based on intrinsic viscosity).
13. Total Aerobic Microbial Count NMT 100 microorganism/gram (as per USP 23, p. 1684).
14. Test for Staphylococcus aureus Staphylococcus aureus is absent (as per USP 23, p. 1684).
15. Test for Pseudomonas aeruginosa Pseudomonas aeruginosa is absent (as per USP 23, p. 1684).
16. Yeasts & Molds NMT 200 CFU/gram (as per USP 23, p.
1686) .
This topical grade may then be sterilized.
Other forms may be suitable such as one form of hyaluronic acid and/or salts thereof (for example, sodium salt) may be an amount also supplied by Hyal Pharmaceutical Corporation. One such amount is a 15 ml vial of Sodium hyaluronate 20mg/ml (300mg/vial - Lot 2F3). The sodium hyaluronate fraction is a 2% solution with a mean average molecular weight of about 225,000. The amount also contains water q.s. which is triple distilled and sterile in accordance with the U.S.P. for injection formulations. The vials of hyaluronic acid and/or salts thereof may be carried in a Type 1 borosilicate glass vial closed by a butyl stopper which does not react with contents of the vial.
The amount of hyaluronic acid and/or salts thereof (for example sodium salt) may comprise hyaluronic acid and/or salts thereof having the following characteristics:
a purified, substantially pyrogen-free fraction of hyaluronic acid obtained from a natural source having at least one characteristic selected from the group consisting of the following:
i) a molecular weight within the range of 150,000 - 225,000;
ii) less than about 1.25% sulphated mucopolysaccharides on a total weight basis;
iii) less than about 0.6% protein on a total weight basis;
iv) less than about 150 ppm iron on a total weight basis;
v) less than about 15 ppm lead on a total weight basis;
vi) less than 0.0025% glucosamine;
vii) less than 0.025% glucuronic acid;
viii) less than 0.025% N-acetylglucosamine;
ix) less than 0.0025% amino acids;
x) a UV extinction coefficient at 257 nm of less than about 0.275;
xi) a UV extinction coefficient at 280 nm of less than about 0.25;
and, xii) a pH within the range of 7.3 - 7.9. Preferably, the hyaluronic acid is mixed with water and the fraction of hyaluronic acid fraction has a mean average molecular weight within the range of 150,000 - 225,000.
Preferably this amount of hyaluronic acid comprises at least one characteristic selected from the group consisting of the following characteristics:
i) less than about 1% sulphated mucopolysaccharides on a total weight basis;
ii) less than about 0.4% protein on a total weight basis;
iii) less than about 100 ppm iron on a total weight basis;
iv) less than about 10 ppm lead on a total weight basis;
v) less than 0.00166% glucosamine;
vi) less than 0.0166% glucuronic acid;
vii) less than 0.016% N-acetylglucosamine;
viii) less than 0.00166% amino acids;
ix) a UV extinction coefficient at 257 nm of less than about 0.23;
x) a UV extinction coefficient at 280 nm of less than 0.19; and xi) a pH within the range of 7.5 - 7.7 Other forms of hyaluronic acid and/or its salts may be chosen from other suppliers, for example those described in prior art documents disclosing forms of hyaluronic acid having lower molecular weights between about 150,000 daltons and 750,000 daltons (protein standard) being prepared as for example, 1-2%
solutions in sterile water for intravenous administration. In addition, sodium hyaluronate produced and supplied by LifeCoreTM Biomedical, Inc. having the following specifications may be suitable (if sterile):
Characteristics Specification Appearance White to cream colored particles Odor No perceptible odor Viscosity Average < 750,000 Daltons Molecular Weight UV/Vis Scan, 190-820nm Matches reference scan OD, 260nm < 0.25 OD units Hyaluronidase Sensitivity Positive Response IR Scan Matches reference pH, 10mg/g solution 6.2 - 7.8 Water 8% maximum Protein < 0.3 mcg/mg NaHy Acetate < 10.0 mcg/mg NaHy Heavy Metals, maximum ppm As Cd Cr Co Cu Fe Pb Hg N i 2.0 5.0 5.0 10.0 10.0 25.0 10.0 10.0 5.0 Microbial Bioburden None observed Endotoxin < 0.07EU/mg NaHy Biological Safety Testing Passes RabbitOcular Toxicity Test The following references teach hyaluronic acid, sources thereof and processes of the manufacture and recovery thereof.
Canadian Letters Patent 1,205,031 (which refers to United States Patent 4,141,973 as prior art) refers to hyaluronic acid fractions having average molecular weights of from 50,000 to 100,000; 250,000 to 350,000; and 500,000 to 730,000 and discusses processes of their manufacture Where high molecular weight hyaluronic acid (or salts or other forms thereof) is used, it must, prior to use be diluted to permit administration and ensure no intramuscular coagulation. Recently, it has been found that large molecular weight hyaluronic acid having a molecular weight exceeding about 1,000,000 daltons self-aggregates and thus, does not interact very well with HA
receptors. Thus, the larger molecular weight hyaluronic acid (such as HealonTM) should be avoided.
Thus, according to an aspect of the invention, the invention provides a composition comprising a therapeutically effective amount of paclitaxel with a 10 therapeutically effective amount of hyaluronic acid and/or a pharmaceuticallyacceptable salt thereof, together with a pharmaceutically-acceptable diluent wherein the therapeutically effective amount of paclitaxel is at a significantlyreduced level than would be normally used (for example greater than three times less). Thus the amount of paclitaxel reduced from that normally used, is 15 "spared" .
The invention also provides a method of treatment of a pathological condition in a subject in need of such treatment, comprising the step of administering an effective dose of a composition according to the invention to said subject over such period as may be required. For example, the treatment 20 may continue for months. However in each instance the effective amount of the agent is "spared".
The invention also provides the use of a composition comprising a form of hyaluronan and an effective dosage amount of paclitaxel for treating a pathological condition (cancer) and wherein the therapeutically effective amount25 of paclitaxel is at a significantly reduced level than would be normally used (for example greater than three times less).
It will be clearly understood that the dose and route of administration will depend upon the condition to be treated, and the attending physician will readily be able to determine suitable doses and routes.
The subject to be treated may be a human (or may be an animal).
The invention further provides a method of preparing a composition of the invention, comprising the step of combining such highly lipophilic therapeutic compound paclitaxel with hyaluronan and/or a pharmaceutically-acceptable salt thereof, and a diluent (such as sterile water) and put into a suitable pharmaceutically acceptable tolerable form (which is of course, non-toxic). The 10 agent once again will be "spared". The inventors believe that the unique attraction between hydrophobic patches of the hyaluronan and paclitaxel enable the paclitaxel to be "spared".
While hyaluronan (HA) is generally hydrophilic, it has these hydrophobic patches which Applicants believe permit the binding/association of the 15 hyaluronan with the paclitaxel. These hydrophobic patches are dispersed on the molecule. Because of the dispersion and lack of knowledge of the exact positions, it is not known if any particular compound combined with the hyaluronan would be capable of being spared to provide effective dosages to the patient.
The invention will now be illustrated with reference to the following tests 20 which illustrate the invention.
The tumour model used in the tests was that described in detail on pages 59 - 60 of Fourth International Workshop - on Hyaluronan in Drug Delivery as follows:
Colon-26 cells Colon-26 cells, a gift from the Imperial Cancer Research Fund (London), were maintained in antibiotic supplemented DMEM
containing 10% fetal calf serum at 37~C in 95% oxygen/5% carbon dioxide.
Tumour Induction Anaesthetized BALB/c mice were subcutaneously implanted with sponges (8 x 4 mm) and seeded with 106 Colon-26 cells three days later by injection.
5 The tumours were allowed to establish for 4 days before dosing was initiated.
Dosing was intravenous (0.25ml/day) for 6 days of amounts as shown in the table below and the tumours were excised 24 hours after the last dose. The data so farrelates to wet and dry weights of the tumour mass, and is shown in the following table:
Group n Wet Weight/mg Dry Weight/mg Control PBS 7 470 15 84.5+4.2 Cremophor 9 514+ 39 94.4+ 7.8 Taxol 2.5mg/kg 6 482 37 81.7 9.2 Taxol 10mg/kg 8 464+ 30 73.9 + 6.4 HA7.5mg/kg 7 485 28 72.1 + 5.3~
Taxol 2.5mg/kg + 8 391 + 38~ 60.4 + 8.0~*
HA 7.5mg/kg ~ p<0.05 ~ ~ p<0.01 comparison with Cremophor control.
HA = hyaluronan (sodium hyaluronate (EM) having a molecular weight between 50,000 and 750,000 daltons (protein standard) Taxol was solubilised in a mixture of 1:1 ethanol and cremophor EL.
15 Further dilution was in sterile PBS. The final cremophor concentration in allTaxol groups was 1.6%. A similar solution served as vehicle control (the cremophor group in the table above).The HA alone should be compared with the PBS control group. Numbers refer to dose in mg/kg.
The dry weights are of particular interest. We have a dose response reduction in dry weight with Taxol, and the combination of low dose Taxol with HA gives the greatest suppression of all.
To note: the reduction in tumour weight caused by HA alone; this is 5 significant only against the Cremophor and not the PBS control. Nonetheless, the data speaks for itself and demonstrates that HA had no detrimental effect ontumour growth. In fact it appears to suppress tumour growth possibly to the same extent as the high dose Taxol. (See PCT application WO 95/30423). The form of HA and TaxolTM may be administered in any suitable manner such as by 10 direct injection, intravenous administration etc.
As many changes can be made to the embodiments without departing from the scope of the invention, it is intended that all material contained herein be interpreted as illustrative of the invention and not in a limiting sense.
Claims (10)
1. A dosage amount of a pharmaceutical composition, the dosage amount comprising an effective amount of a form of hyaluronan selected from the group consisting of hyaluronic acid and pharmaceutically acceptable salts thereof having a molecular weight less than 750,000 daltons (Protein Standard), suitableexcipients for administration and an effective amount of paclitaxel which is less than the usual dosage amount of the medicine when administered alone in suitable excipients.
2. The dosage amount of the pharmaceutical composition of claim 1 wherein the amount of medicine in the dosage amount is at least about 3 times less than the usual dosage amount administered for treatment.
3. The dosage amount of claim 2 wherein the molecular weight of hyaluronan is greater than 150,000 daltons.
4. A method of treating a patient suffering a disease or condition comprising administering a dosage amount according to claim 1, 2 or 3 to the patient for such period of time as required.
5. The use of hyaluronan and a lesser amount of taxol than is normally used to treat a disease in the manufacture of a dosage amount of a pharmaceutical composition wherein the dosage amount comprises an effective amount of each of, a form of hyaluronan selected from the group consisting of hyaluronic acid and pharmaceutically acceptable salts thereof having a molecular weight less than 750,000 daltons (Protein Standard), suitable excipients for administration and paclitaxel which is present in the dosage amount in an amount less than the usual dosage amount of the medicine when administered alone.
6. The use of claim 5 wherein the amount of the paclitaxel in the dosage amount is at least about 3 times less than the usual dosage amount administered during treatment.
7. The use of claim 5 or 6 wherein the molecular weight of the form of hyaluronan exceeds about 150,000 daltons.
8. The use of hyaluronan having a molecular weight less than 750,000 daltons (protein standard) and an amount of paclitaxel less than the amount of paclitaxel normally used to treat pathological tissue which expresses excess hyaluronan receptors.
9. The use of claim 8 wherein the amount of the paclitaxel in the dosage amount is at least about 3 times less than the usual dosage amount administered during treatment.
10. The use of claim 8 or 9 wherein the molecular weight of the form of hyaluronan exceeds about 150,000 daltons.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002208924A CA2208924A1 (en) | 1997-07-09 | 1997-07-09 | Sparing paclitaxel by the use of hyaluronan |
| AU82031/98A AU8203198A (en) | 1997-07-09 | 1998-07-08 | Paclitaxel compositions containing hyaluronic acid of a molecular weight of lessthan 750.000 da |
| PCT/CA1998/000660 WO1999002151A1 (en) | 1997-07-09 | 1998-07-08 | Paclitaxel compositions containing hyaluronic acid of a molecular weight of less than 750.000 da |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002208924A CA2208924A1 (en) | 1997-07-09 | 1997-07-09 | Sparing paclitaxel by the use of hyaluronan |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2208924A1 true CA2208924A1 (en) | 1999-01-09 |
Family
ID=4160954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002208924A Abandoned CA2208924A1 (en) | 1997-07-09 | 1997-07-09 | Sparing paclitaxel by the use of hyaluronan |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU8203198A (en) |
| CA (1) | CA2208924A1 (en) |
| WO (1) | WO1999002151A1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002534484A (en) * | 1999-01-13 | 2002-10-15 | メディテック リサーチ リミテッド | Compositions and methods for enhancing drug efficacy |
| US8287894B2 (en) | 2000-07-14 | 2012-10-16 | Alchemia Oncology Pty Limited | Hyaluronan as a drug pre-sensitizer and chemo-sensitizer in the treatment of disease |
| US8623354B2 (en) | 2005-09-07 | 2014-01-07 | Alchemia Oncology Pty Limited | Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment |
| US8937052B2 (en) | 2005-07-27 | 2015-01-20 | Alchemia Oncology Pty Limited | Therapeutic protocols using hyaluronan |
| US9066919B2 (en) | 2000-07-14 | 2015-06-30 | Alchemia Oncology Pty Limited | Hyaluronan as a chemo-sensitizer in the treatment of cancer |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6593308B2 (en) * | 1999-12-03 | 2003-07-15 | The Regents Of The University Of California | Targeted drug delivery with a hyaluronan ligand |
| JP4215429B2 (en) | 1999-12-28 | 2009-01-28 | バイオニケ ライフ サイエンシーズ インコーポレイテッド | Hyaluronic acid in cancer treatment |
| IT1318403B1 (en) | 2000-03-17 | 2003-08-25 | Cooperativa Ct Ricerche Poly T | POLYSACCHARID ESTERS OF N-DERIVATIVES OF GLUTAMIC ACID. |
| ITPD20020271A1 (en) | 2002-10-18 | 2004-04-19 | Fidia Farmaceutici | CHEMICAL-PHARMACEUTICAL COMPOUNDS CONSISTING OF TAXAN DERIVATIVES COVALENTLY LINKED TO HYALURONIC ACID OR ITS DERIVATIVES. |
| AU2003284885A1 (en) * | 2002-10-21 | 2004-05-13 | Kensey Nash Corporation | Device and methods for sequential, regional delivery of multiple cytotoxic agents |
| EP1569616A2 (en) | 2002-12-04 | 2005-09-07 | Technologies Biolactis Inc. | An exopolysaccharides delivery system for active molecules |
| PT2543357T (en) * | 2011-07-07 | 2018-04-30 | Holy Stone Healthcare Co Ltd | Composition for use in treating and preventing inflammation related disorder |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8900422D0 (en) * | 1989-02-08 | 1989-02-08 | Pharmacia Ab | CIRCULATED HYALURONATE GELS AND PROCEDURES FOR PREPARING THESE |
| CA2122519C (en) * | 1994-04-29 | 2001-02-20 | Rudolf Edgar Dr. Falk | Cancer treatment and metastasis prevention |
| AU4406793A (en) * | 1992-06-04 | 1993-12-30 | Clover Consolidated, Limited | Water-soluble polymeric carriers for drug delivery |
| SE9301422D0 (en) * | 1993-04-28 | 1993-04-28 | Kabi Pharmacia Ab | METHOD AND MEANS FOR INHIBITING POSTERIOR CAPSULE OPACIFICATION |
-
1997
- 1997-07-09 CA CA002208924A patent/CA2208924A1/en not_active Abandoned
-
1998
- 1998-07-08 AU AU82031/98A patent/AU8203198A/en not_active Abandoned
- 1998-07-08 WO PCT/CA1998/000660 patent/WO1999002151A1/en active Application Filing
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002534484A (en) * | 1999-01-13 | 2002-10-15 | メディテック リサーチ リミテッド | Compositions and methods for enhancing drug efficacy |
| JP4790911B2 (en) * | 1999-01-13 | 2011-10-12 | アルケミア オンコロジー ピーティワイ リミテッド | Compositions and methods for enhancing the efficacy of drugs |
| US8741970B2 (en) | 1999-01-13 | 2014-06-03 | Alchemia Oncology Pty Limited | Composition and method for the enhancement of the efficacy of drugs |
| US8287894B2 (en) | 2000-07-14 | 2012-10-16 | Alchemia Oncology Pty Limited | Hyaluronan as a drug pre-sensitizer and chemo-sensitizer in the treatment of disease |
| US8388993B2 (en) | 2000-07-14 | 2013-03-05 | Alchemia Oncology Pty Limited | Hyaluronan-chemotherapeutic agent formulations for the treatment of colon cancer |
| US9066919B2 (en) | 2000-07-14 | 2015-06-30 | Alchemia Oncology Pty Limited | Hyaluronan as a chemo-sensitizer in the treatment of cancer |
| US8937052B2 (en) | 2005-07-27 | 2015-01-20 | Alchemia Oncology Pty Limited | Therapeutic protocols using hyaluronan |
| US8623354B2 (en) | 2005-09-07 | 2014-01-07 | Alchemia Oncology Pty Limited | Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999002151A1 (en) | 1999-01-21 |
| AU8203198A (en) | 1999-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6537978B1 (en) | Oral administration of effective amounts of forms of hyaluronic acid | |
| US6475795B1 (en) | Use of hyaluronan in gene therapy | |
| US8778908B2 (en) | Cystitis treatment with high dose chondroitin sulfate | |
| CA2122519C (en) | Cancer treatment and metastasis prevention | |
| CA2208924A1 (en) | Sparing paclitaxel by the use of hyaluronan | |
| US5674857A (en) | Use of hyaluronic acid to repair ischemia reperfusion damage | |
| CA2175282A1 (en) | Use of forms of hyaluronic acid (ha) for the treatment of cancer | |
| AP619A (en) | Use of hyaluronic acid or salt for the treatment of a human having a stroke or myocardial infarction. | |
| US5817642A (en) | Clearing of atherosclerosis | |
| JP4210330B2 (en) | Hyaluronic acid receptor binding agent and method of use thereof | |
| US6596703B1 (en) | Promotion of wound healing utilizing steroids having reduced deteriorous systemic side effects typical of glucocorticoids, mineralocorticoids and sex steroids | |
| US5817644A (en) | Targeting of dosages of medicine and therapeutic agents | |
| CA2122551A1 (en) | Clearing of atherosclerosis | |
| RU2739184C1 (en) | Pharmaceutical agent for arthritic diseases treatment | |
| RU2739747C1 (en) | Pharmaceutical agent for arthritic diseases treatment | |
| EA041405B1 (en) | PHARMACEUTICAL FOR THE TREATMENT OF ARTHROLOGICAL DISEASES | |
| EA041409B1 (en) | PHARMACEUTICAL FOR THE TREATMENT OF ARTHROLOGICAL DISEASES | |
| CA2131130A1 (en) | Modulation of cellular activity | |
| CA2164260C (en) | Targeting of dosages of medicines and therapeutic agents | |
| DE69634993T2 (en) | USE OF HYALURONAN IN GENE THERAPY | |
| CA2193921A1 (en) | Oral administration of effective amounts of forms of hyaluronic acid according to various standards |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |